Coming Soon to MedCare Health Clinic & Pharmacy
Foundayo (orforglipron) weight loss pill is a once-daily oral GLP-1 receptor agonist developed by Eli Lilly and Company for the treatment of obesity, overweight with related medical conditions, and type 2 diabetes.
Unlike injectable GLP-1 treatments such as Mounjaro (tirzepatide) and Wegovy (semaglutide), Foundayo is taken as a simple daily tablet, offering a needle-free alternative for patients who prefer oral medication.
Foundayo belongs to a new class of small-molecule GLP-1 medicines, meaning it does not require injection and can be taken with or without food at any time of the day.
Clinical studies have shown that Foundayo can support significant weight loss, appetite reduction, and improved blood sugar control, making it one of the most promising oral obesity treatments currently being developed.
Foundayo weightloss pill will be available at MedCare Health Clinic & Pharmacy once approved by the UK regulator.
Foundayo works by activating the GLP-1 (glucagon-like peptide-1) receptor, a hormone pathway that plays an important role in appetite regulation and blood sugar control.
By mimicking natural GLP-1 signalling, Foundayo can help support weight loss through several mechanisms:
The medication acts on appetite centres in the brain, helping reduce hunger and food cravings.
Patients often feel full sooner and remain satisfied for longer after meals, which can reduce overall calorie intake.
Food remains in the stomach for longer, contributing to prolonged fullness after eating.
GLP-1 receptor activation stimulates insulin release and reduces glucagon secretion, helping stabilise blood glucose levels in people with Type 2 Diabetes.
These combined effects contribute to clinically meaningful and sustainable weight loss when used alongside diet and lifestyle changes.
Mounjaro is a weekly injectable medication that activates both the GLP-1 and GIP receptors, whereas Foundayo activates GLP-1 only.
Key differences include:
| Feature | Foundayo | Mounjaro |
|---|---|---|
| Form | Oral tablet | Weekly injection |
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual agonist |
| Convenience | Tablet taken daily | Injection once weekly |
| Average weight loss | ~11% body weight | Up to ~22.5% body weight |
While injectable treatments currently demonstrate greater average weight loss, Foundayo may be a preferred option for patients who want an effective oral alternative.
Both Foundayo and Wegovy target the GLP-1 receptor, but they differ in formulation and administration.
The Wegovy tablet (oral semaglutide) is a peptide-based medication that must be taken on an empty stomach with strict timing around food and drink.
Foundayo, however, is a small-molecule medicine, meaning it:
This flexibility may make Foundayo more convenient for many patients.
Clinical studies have demonstrated promising results for Foundayo in both obesity and diabetes populations.
In Phase 3 trials:
• Participants without diabetes lost approximately 11% of their body weight over 72 weeks
• Participants with type 2 diabetes lost around 10.5% of body weight
• Placebo groups lost approximately 2% of body weight
These results demonstrate that Foundayo can provide clinically meaningful weight loss without injections.
Foundayo is being developed for adults who:
• Have obesity (BMI ≥30)
• Are overweight (BMI ≥27) with weight-related health conditions
• Have type 2 diabetes requiring improved blood sugar control
Weight-related health conditions may include:
A clinical assessment is always required before treatment is prescribed.
Foundayo is taken as one tablet once daily.
Key instructions:
• Swallow the tablet whole
• Do not crush or chew the tablet
• Can be taken with or without food
• Can be taken at any time of day
Treatment typically begins with a lower starting dose, which is gradually increased over time to help minimise gastrointestinal side effects.
Consistent daily use helps maintain stable therapeutic levels in the body.
Treatment with Foundayo (orforglipron) usually begins with a gradual dose escalation. This step-up approach helps the body adjust to the medication and can reduce the likelihood of gastrointestinal side effects commonly associated with GLP-1 treatments.
The typical dosing schedule is:
Weeks 1-4:
0.8 mg once daily (starting dose)
Weeks 5-8:
2.5 mg once daily
Weeks 9-12:
5.5 mg once daily
Week 13 onwards:
Your clinician may increase the dose further depending on your response and tolerance to treatment. Maintenance doses may include 9 mg, 14.5 mg, or 17.2 mg once daily.
Dose adjustments are always made under medical supervision to ensure safe and effective treatment.
If you forget to take a dose of Foundayo, take it as soon as you remember on the same day.
Do not take more than one tablet in a single day to make up for a missed dose.
For best results, take Foundayo consistently at the same time each day and always follow the dosing instructions provided by your prescribing clinician.
As with other GLP-1 medications, the most commonly reported side effects are gastrointestinal.
These may include:
• Nausea
• Diarrhoea
• Constipation
• Indigestion
• Abdominal discomfort
• Bloating
• Vomiting
These effects are usually mild to moderate and tend to improve as the body adjusts to the medication.
If symptoms persist or worsen, medical advice should be sought.
Foundayo is a prescription-only medicine and should only be used following a medical consultation.
It may not be suitable for individuals who:
• Are pregnant or breastfeeding
• Are under 18 years old
• Have a history of pancreatitis
• Have certain gastrointestinal disorders
Always inform your clinician about any medications you are taking, particularly those that affect blood sugar levels.
Although Foundayo has received regulatory approval in the United States, it is not yet approved by the UK regulator Medicines and Healthcare products Regulatory Agency (MHRA).
Following approval, Foundayo is expected to become available through regulated UK clinics and pharmacies.
MedCare Health Clinic & Pharmacy plans to offer Foundayo as soon as UK authorisation is granted.
At MedCare Health Clinic & Pharmacy, patient safety and clinical care are our top priorities.
Our treatments are prescribed by experienced pharmacist prescribers and clinicians.
Complete a secure online consultation to determine whether treatment is suitable for you.
Choose home delivery or in-clinic collection for maximum convenience and privacy.
We offer a full range of evidence-based treatments including:
• Mounjaro
• Wegovy
• Foundayo (coming soon)
The Foundayo pill (orforglipron) is a once-daily oral GLP-1 receptor agonist designed to help with weight management and blood sugar control. Unlike injectable treatments, it is taken as a tablet, offering a needle-free alternative for people seeking GLP-1 therapy.
Foundayo is taken as a daily tablet rather than a weekly injection, making it a convenient alternative for patients who prefer oral medication.
No. Foundayo is not yet approved in the UK and cannot currently be prescribed or supplied.
Yes. Once approved by the MHRA, MedCare Health Clinic & Pharmacy plans to offer Foundayo following an online medical consultation.
Yes. Clinical studies show that Foundayo may support weight loss in people with obesity both with and without diabetes.
Yes. Foundayo is a prescription-only medicine (POM) and requires a clinical review before treatment can be supplied.
Clinical studies of Foundayo (orforglipron) have shown that patients may lose around 10–11% of their body weight over approximately 72 weeks when the medication is used alongside a reduced-calorie diet and increased physical activity. Individual results vary depending on factors such as starting weight, dosage, adherence to treatment, and lifestyle changes.
Both Foundayo and Mounjaro are developed by Eli Lilly and Company, but they work slightly differently. Mounjaro activates both GLP-1 and GIP receptors and has shown greater average weight loss in clinical trials. However, Foundayo may be preferred by patients who want a daily tablet instead of weekly injections.
No. Foundayo and Wegovy both target the GLP-1 receptor but are different medicines. Wegovy is typically given as a weekly injection, while Foundayo is a once-daily tablet, making it a convenient oral option for some patients.
Yes. Because Foundayo activates the GLP-1 receptor, it can help regulate blood sugar levels and improve insulin secretion in people with Type 2 Diabetes. Clinical trials have shown reductions in HbA1c levels in patients using the medication.
Although Foundayo has been approved in the United States, it must still be authorised by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) before it becomes available in the UK. Availability is expected after regulatory review, which may occur in late 2026 or early 2027.
Emerging clinical evidence suggests that Foundayo may help maintain weight loss after patients stop injectable GLP-1 medications such as Mounjaro or Wegovy. Some studies indicate it may support long-term weight maintenance when transitioning from injectable treatments to an oral tablet.
Yes. Like other GLP-1 medications, Foundayo works best when combined with healthy eating habits and regular physical activity. The medication helps reduce appetite and improve satiety, making it easier to maintain a calorie-controlled diet.
Clinical trials suggest that Foundayo is generally well tolerated when used long term under medical supervision. Most side effects are mild to moderate and occur during the early dose escalation period. Ongoing monitoring by a healthcare professional is recommended.
Can Foundayo be taken with other medications?
Foundayo may interact with certain medicines that affect blood sugar levels or digestion. Before starting Foundayo, patients should inform their Prescriber about any prescription medicines, over-the-counter treatments, or supplements they are taking.
The price of Foundayo in the UK has not yet been officially confirmed. Pricing will likely depend on regulatory approval, supply availability, and pharmacy providers. As a small-molecule oral treatment developed by Eli Lilly and Company, it may eventually be priced competitively compared with injectable GLP-1 medications.
The Foundayo pill is currently awaiting approval from the UK regulator, the Medicines and Healthcare products Regulatory Agency. If approved, the Foundayo pill could become available in the UK through regulated clinics and pharmacies following medical consultation.
At present, Foundayo cannot be legally purchased in the UK because it has not yet received authorisation from the Medicines and Healthcare products Regulatory Agency. Once approved, it will only be available through prescription-based medical services.
While the UK price of Foundayo has not yet been confirmed, it may eventually offer a more affordable alternative to injectable medications like Mounjaro and Wegovy. Oral medicines are typically simpler to manufacture than injectable peptide therapies.
Currently, the Foundayo pill UK market does not have access to the medication. It is expected to become available privately through Medcare HEalth Clinics once regulatory approval is granted.
The main difference with the Foundayo pill is that it is a non-peptide GLP-1 medication taken orally. This means patients may benefit from GLP-1 weight loss treatment without weekly injections.
Once approved in the UK, Foundayo is expected to be prescribed by licensed clinics and pharmacies following an online or in-person medical consultation.
Many experts expect Foundayo to become a popular option in the Foundayo UK weight loss market because it combines the benefits of GLP-1 therapy with the convenience of a daily tablet.
Interest in the Foundayo pill has grown because it offers a new oral alternative to injectable weight loss medications. Many patients prefer tablets over injections, making Foundayo a potentially attractive option once available.
Reviews
There are no reviews yet.